Experimental chemotherapy for Chagas disease: 15 years of research contributions from in vivo and in vitro studies

Memórias do Instituto Oswaldo Cruz

Maria De Nazaré C Soeiro²  Andréia P Dantas¹  Anissa Daliry²  Cristiane F Da Silva²  Denise Gj Batista²  Elen M De Souza²  Gabriel M Oliveira²  Kelly Salomão²  Marcos Meuser Batista²  Michelle Go Pacheco²  Patrícia Bernardino Da Silva²  Ricardo M Santa-rita¹  Rubem Fs Menna Barreto²  David W Boykin¹  Solange Lisboa De Castro² 

[1] ,Instituto Oswaldo Cruz Laboratório de Biologia Celular

关键词: Trypanosoma cruzi;    Chagas disease;    experimental chemotherapy;    aromatic diamidines;    propolis;    N;    N-dimethyl-propenamines;    naphthoquinones;   

DOI  :  10.1590/S0074-02762009000900040

来源: SciELO

【 摘 要 】

Chagas disease, which is caused by the intracellular parasite Trypanosoma cruzi, is a neglected illness with 12-14 million reported cases in endemic geographic regions of Latin America. While the disease still represents an important public health problem in these affected areas, the available therapy, which was introduced more than four decades ago, is far from ideal due to its substantial toxicity, its limited effects on different parasite stocks, and its poor activity during the chronic phase of the disease. For the past 15 years, our group, in collaboration with research groups focused on medicinal chemistry, has been working on experimental chemotherapies for Chagas disease, investigating the biological activity, toxicity, selectivity and cellular targets of different classes of compounds on T. cruzi. In this report, we present an overview of these in vitro and in vivo studies, focusing on the most promising classes of compounds with the aim of contributing to the current knowledge of the treatment of Chagas disease and aiding in the development of a new arsenal of candidates with anti-T. cruzi efficacy.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License